Acute Myeloid Leukemia: key endpoint results by drug
The key endpoints of Acute Myeloid Leukemia trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Acute Myeloid Leukemia page.
OS, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Durvalumab | 11.6 | 14.4 (Azacitidine) | — | n 42 | NCT02775903 Phase 2, secondary |
| Gilteritinib | 9.8 | 9.2 (AZA) | — | n 89 | NCT02752035 Phase 3, primary |
| Glasdegib | 17.3 | 20.4 | −3.1 | n 201 | NCT03416179 Phase 3, primary |
| Quizartinib | 31.9 | 15.1 | +16.8 | n 268 | NCT02668653 Phase 3, primary |
| Selinexor | 3.1 | 5.6 (Physician's Choice) | — | 60 mg (Equivalent to 35 mg/m^2) · n 118 | NCT02088541 Phase 2, primary |
| Vyxeos | 9.6 | 6.0 (7+3) | — | n 153 | NCT01696084 Phase 3, primary |
| Atezolizumab | 5.8b | — | — | 120 mg + 840 mg · n 3 | NCT03730012 Phase 1/2, secondary |
| Azacitidine | 10.4b | — | — | n 241 | NCT01074047 Phase 3, primary |
| Crenolanib | 7.8b | — | — | n 13 | NCT01657682 Phase 2, secondary |
| Daratumumab | 3.6b | — | — | n 16 | NCT02807558 Phase 2, secondary |
| Enasidenib | 6.5b | — | — | n 158 | NCT02577406 Phase 3, primary |
| Gemtuzumab Ozogamicin | 27.9b | — | — | n 138 | NCT00049517 Phase 3, secondary |
| Midostaurin | 6.2b | — | — | n 26 | NCT03092674 Phase 2/3, primary |
| Nivolumab | 6.2b | — | — | n 26 | NCT03092674 Phase 2/3, primary |
| Olutasidenib | 11.6b | — | — | n 153 | NCT02719574 Phase 1/2, secondary |
| Pembrolizumab | 42.2b | — | — | 200 mg · n 12 | NCT02708641 Phase 2, secondary |
Drugs checked with no result here: 45 not reported, 3 not posted, 18 trial running.
Complete remission
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Gemtuzumab Ozogamicin | 69% | 68.6% (Ara-C+Daunomycin) | — | n 300 | NCT00085709 Phase 3, primary |
| Gilteritinib | 21.1% | 10.5% (Salvage Chemotherapy) | — | wk 24 · n 247 | NCT02421939 Phase 3, secondary |
| Selinexor | 5.1% | 0% (Physician's Choice) | — | 60 mg (Equivalent to 35 mg/m^2) · n 118 | NCT02088541 Phase 2, secondary |
| Vyxeos | 48.8% | 48.8% (Cytarabine + Daunorubicin) | — | n 84 | NCT00788892 Phase 2, primary |
| Atezolizumab | 33.3%b | — | — | 120 mg + 420 mg · n 3 | NCT03730012 Phase 1/2, secondary |
| Azacitidine | 13.3%b | — | — | 400 mg + 75 mg · n 30 | NCT03941964 Phase 3, secondary |
| Enasidenib | 23.4%b | — | — | n 158 | NCT02577406 Phase 3, secondary |
| Pembrolizumab | 37.8%b | — | — | n 37 | NCT02768792 Phase 2, primary |
| Quizartinib | 2.6%b | — | — | 60 mg · wk 156 · n 38 | NCT01565668 Phase 2, secondary |
| Tretinoin | 100%b | — | — | wk 208 · n 16 | NCT01404949 Phase 2, secondary |
| Venetoclax | 13.3%b | — | — | 400 mg + 75 mg · n 30 | NCT03941964 Phase 3, secondary |
Drugs checked with no result here: 49 not reported, 4 not posted, 18 trial running.
Event-free survival, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Azacitidine | 17.7 | 15.7 (Azacitidine) | — | 20 mg/m^2 + 75 mg/m^2 · n 227 | NCT03268954 Phase 3, primary |
| Gilteritinib | 0.0 | 0.0 (AZA) | — | n 89 | NCT02752035 Phase 3, secondary |
| Ivosidenib | 0.0 | 0.0 | ±0 | n 72 | NCT03173248 Phase 3, primary |
| Midostaurin | 6.0 | 5.9 | +0.1 | n 250 | NCT03512197 Phase 3, primary |
| Quizartinib | 0.0 | 0.7 | −0.7 | n 268 | NCT02668653 Phase 3, secondary |
| Venetoclax | 7.7 | 11.2 (Venetoclax + Azacitidine) | — | 20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 · n 83 | NCT04266795 Phase 2, primary |
| Vyxeos | 2.5 | 1.3 (7+3) | — | n 153 | NCT01696084 Phase 3, secondary |
| Atezolizumab | 5.8b | — | — | 120 mg + 420 mg · n 3 | NCT03730012 Phase 1/2, secondary |
| Daratumumab | 1.2b | — | — | n 16 | NCT02807558 Phase 2, secondary |
| Enasidenib | 4.9b | — | — | n 158 | NCT02577406 Phase 3, secondary |
| Nivolumab | 3.6b | — | — | n 26 | NCT03092674 Phase 2/3, secondary |
| Olutasidenib | 5.5b | — | — | n 153 | NCT02719574 Phase 1/2, secondary |
| Selinexor | 4.3b | — | — | 60 mg flat dose · n 15 | NCT02249091 Phase 2, secondary |
| Tretinoin | 1.4b | — | — | 6 mg/kg/day + 45 mg/m^2/day · n 4 | NCT02842827 Phase 1/2, primary |
Drugs checked with no result here: 48 not reported, 17 trial running, 3 not posted.
Duration of response, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Azacitidine | 17.1 | 18.3 (Azacitidine) | — | 20 mg/m^2 + 75 mg/m^2 · n 64 | NCT03268954 Phase 3, secondary |
| Durvalumab | 5.7 | 12 (Azacitidine) | — | n 20 | NCT02775903 Phase 2, secondary |
| Gilteritinib | 14.8 | 1.8 (Salvage Chemotherapy) | — | n 52 | NCT02421939 Phase 3, secondary |
| Selinexor | 6.7 | 4.9 (Physician's Choice) | — | 60 mg (Equivalent to 35 mg/m^2) · n 16 | NCT02088541 Phase 2, secondary |
| Vyxeos | 6.9 | 6.1 (7+3) | — | n 153 | NCT01696084 Phase 3, secondary |
| Brentuximab Vedotin | 2.9b | — | — | n 7 | NCT01461538 Phase 2, secondary |
| Enasidenib | 7.4b | — | — | n 64 | NCT02577406 Phase 3, secondary |
| Midostaurin | 0.9b | — | — | 200 mg/day · n 13 | NCT00045942 Phase 1/2, secondary |
| Olutasidenib | 14.8b | — | — | n 75 | NCT02719574 Phase 1/2, secondary |
| Pembrolizumab | 12.0b | — | — | n 2 | NCT02981914 Phase 1, secondary |
| Quizartinib | 3.6b | — | — | n 83 | NCT00989261 Phase 2, secondary |
Drugs checked with no result here: 47 not reported, 6 not posted, 18 trial running.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 82 approved or late-stage drugs with a featured trial in Acute Myeloid Leukemia were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.